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Abstract
Vertebrobasilar dolichoectasia (VBD) is a chronic disorder with various cerebrovascular and compressive manifestations, involving
subarachnoid hemorrhage (SAH). Occurrence of SAH shortly after worsening of clinical VBD symptoms has occasionally been
reported. The goal of the study was to examine this association, in particular its pathophysiology, clinical precursor signs, time
course, and outcome.
To this end, in a retrospective multicenter study, we analyzed 20 patients with VBD and SAH in regard to preceding clinical
symptoms, presence of vertebrobasilar thrombosis and ischemia, outcome and neuropathological correlates.
Median age of the 7 female and 13 male patients was 70 years (interquartile range [IQR] 18.3 years). Fourteen patients (70%)
presented with new or acutely worsening posterior fossa signs at a median of 3 days prior to SAH (IQR 2, range 0.5–14). A thrombus
within the VBDwas detected in 12 patients (60%). Thrombus formation was associated with clinical deterioration (x2=4.38, P=0.04)
and ponto-cerebellar ischemia (x2=8.09, P=0.005). During follow-up after SAH, 13 patients (65%) died, after a median survival time
of 24hours (IQR 66.2, range 2–264hours), with a signiﬁcant association between proven ponto-cerebellar ischemia and case fatality
(x2=6.24, P=0.01).
The data establish an association between clinical deterioration in patients with VBD, vertebrobasilar ischemia, and subsequent
SAH. Antithrombotic treatment after deterioration appears controversial and SAH outcome is frequently fatal. Our data also indicate a
short window of 3 days that may allow for evaluating interventional treatment, preferably within randomized trials.
Abbreviations: CTA = computed tomography angiography, IQR = interquartile range, MRI = magnetic resonance imaging,
SAH = subarachnoid hemorrhage, VBD = vertebrobasilar dolichoectasia.
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11. Introduction
Dolichoectasia refers to winding and dilated arteries,[1,2] and is
associated with arterial hypertension and genetic predisposi-
tion.[3,4] Estimations of dolichoectasia prevalence range from 0.1
to >12 %, with a trend to higher prevalence in more recent
studies,[3,5,6] likely due to increased life expectancy but also more
widespread use of imaging. Dolichoectasia is predominantly
diagnosed around the age of 60,[7] and more often affects the
posterior than anterior cerebral circulation.[1,8] Vertebrobasilar
dolichoectasia (VBD) may cause brainstem and cranial nerve
compression along with corresponding symptoms such as
bilateral or isolated oculomotor deﬁcits,[9] pyramidal and
cerebellar signs,[10,11] trigeminal neuralgia,[7] cranial nerve
deﬁcits,[12] and hydrocephalus.[5,13]
Even more important, ischemia represents a central concern
in VBD and occurs usually in brainstem, pons,[12,14,15] or the
thalamus.[14] Dolichoectasia is present in 12% to 17 % of
patients with cerebral ischemia as indicated byMR angiography,
and VBD is related to 7% of all posterior circulation
ischemic strokes.[2,6,8,16] Another major complication in patients
with VBD are subarachnoid and intraparenchymal
hemorrhage,[5,12,13,15,17–21] with an annual prospective risk
between 1% and 2.5%.[22] Previous reports suggest subarach-
noid hemorrhage (SAH) in VBD may rapidly follow
ischemia.[15,17–25] However, the link between clinical change,
vertebrobasilar thrombosis, posterior circulation ischemia, and
SAH remains largely speculative.
Sokolov et al. Medicine (2016) 95:27 MedicineThe goal of this study was to assess temporal and statistical
associations between SAH and acute clinical worsening,
thrombosis, and ischemia in patients VBD, the role of
antithrombotic treatment, as well as pathophysiology and
outcome of SAH.2. Methods
2.1. Participants
Between 1997 and 2012, all consecutive patients hospitalized at
the principal investigator center (Centre Hospitalier Universitaire
Vaudois, CHUV, Lausanne, Switzerland) who presented with
SAH and no other potential cause than VBDwere included in this
retrospective study. Patients were identiﬁed on daily ward rounds
in neurology, neurosurgery, and intensive care (n=7) and from
the hospital’s database (n=2). Written informed consent was
obtained. Two patients were described in a previous report.[20] In
addition, nonconsecutive patients with SAH due to VBD were
identiﬁed in other cerebrovascular centers in Switzerland, Italy,
India, the United States, and the Netherlands. The study was
approved by the Institutional Ethics Review Board at the CHUV
in Lausanne, Switzerland.Figure 1. Clinico-pathological ﬁndings. (A) Axial CT angiogram and (B)
pathological specimen show vertebrobasilar dolichoectasia (VBD), with its
typical elongation and tortuosity. The basilar trunk is predominantly affected by
VBD. However, as in these cases, dilated caliber of the vertebral arteries can
also occur. CT=computed tomography, VBD=vertebrobasilar dolichoectasia.2.2. Clinical assessment
We analyzed past medical history, cerebrovascular risk factors
and the time interval between VBD diagnosis and the
index admission, if the diagnosis was known prior to
hospitalization. Neurological symptoms at initial diagnosis of
VBD and at admission were evaluated. In patients with
acute clinical deterioration preceding SAH, the time interval
between symptom onset and occurrence of SAH was recorded.
Survival rate and possible associations between different
clinical presentations and outcome were evaluated. Long-term
and acute antithrombotic treatment strategies were also
assessed.
2.3. Radiological and pathological data
VBD and intraluminal thrombus formation was diagnosed by
computed tomography angiography (CTA, Fig. 1A). Initial SAH
diagnosis was established by CT in 19 patients and through
autopsy in one. During the ﬁrst days of hospitalization, most of
the patients also underwent magnetic resonance imaging (MRI)
to examine signs of acute or subacute ischemia (Fig. 2). Collected
radiological variables also included leukoaraiosis and other
vascular abnormalities. Six of the 9 CHUV patients underwent
autopsy.
2.4. Statistical analysis
Median values and interquartile ranges were calculated for age,
symptom duration, and time on prophylactic antithrombotic
treatment, as well as survival after SAH. Proportions reﬂected in
percentage values were calculated for the presence or the absence
of speciﬁc ﬁndings, treatments, and outcomes in the study
population. Chi-square statistics with Yates correction were used
to calculate associations between thrombosis and ischemia,
ischemia and preventive antithrombotic therapy, and between
fatal outcome and clinical presentation (with/without chronic
VBD symptoms; with/without acute clinical change prior
to SAH), thrombosis and ischemia. All tests of signiﬁcance were
2-tailed.23. Results
3.1. Clinical presentation
Among the 7 female and 13 male patients, median age was 70
years (interquartile range [IQR] 18.3 years, range 47–93 years). A
total of 65% of the patients had known VBD, diagnosed at a
Table 1
Clinical presentation of vertebrobasilar dolichoectasia: (A) clinical
picture along with number and percentage of patients affected at
initial diagnosis and during the course of chronic evolution of
vertebrobasilar dolichoectasia (VBD). (B) Newly occurred or
deteriorated symptoms at index admission, with number of
patients and percentage referring to all patients with clinical
change prior to SAH (n=14). Only symptoms observed in at least 2
patients reported.
(A) Chronic symptoms n (%)
Bulbar signs 8 (40)
Ataxia 6 (30)
Facial nerve palsy 4 (20)
Vertigo 4 (20)
Abducens nerve palsy 2 (10)
Hemiplegia 2 (10)
Nystagmus 2 (10)
Headache 2 (10)
(B) Symptoms at worsening (before SAH) n (%)
Ataxia 5 (36)
Vertigo 4 (29)
Headache 4 (29)
Somnolence 3 (21)
Bulbar signs 3 (21)
Hemiplegia 2 (14)
Facial nerve palsy 2 (14)
SAH= subarachnoid hemorrhage; VBD= vertebrobasilar dolichoectasia.
Figure 2. Thrombosis and stroke in dolichoectasia. (A) Axial CT angiogram
revealing thrombosis within the dilated basilar trunk of a vertebrobasilar
dolichoectasia (VBD). (B) Pathological examination showed multilayer acute-
on-chronic thrombi. Only a small residual lumen could be detected. Rupture
site (upper segment of the image) was located at the same level as the
thrombus. (C) Axial diffusion-weighted MRI showing infarction of the left pons
with pontine compression by the dolichoectatic basilar trunk. (D) Diffusion-
weighted MRI with infarction in both cerebellar hemispheres. CT=computed
tomography, MRI=magnetic resonance imaging, VBD=vertebrobasilar
dolichoectasia.
Sokolov et al. Medicine (2016) 95:27 www.md-journal.commedian of 17 months prior to SAH (IQR 45 months, range
0.4–144 months). At initial VBD diagnosis, bulbar symptoms
(especially dysarthria and dysphagia) prevailed, as well as other
posterior fossa symptoms, such as ataxia and vertigo. Diverse
cranial nerve deﬁcits were present, most often unilateral facial
and abducens nerve palsies; hemiplegia and nystagmus were less
common (Table 1A).
New clinical signs or acute deterioration of existing deﬁcits
prior to SAH were observed in 70% of patients (n=14),
preceding SAH by a median of 3 days (IQR 2 days, range 0.5–14
days). Predominant symptoms at worsening were ataxia, vertigo,
headache, alteration of consciousness, and bulbar signs
(Table 1B). One patient each presented with downbeat
nystagmus, a locked-in syndrome or Horner’s syndrome.
Six patients had sudden-onset SAH without preceding clinical
signs. In 4 of these patients, VBD had been previously diagnosed.
In only 1 patient was SAH the initial presentation of VBD.
Another patient was admitted with sudden second SAH due to
known VBD, having survived the initial one. Examining the
etiology of all SAH patients admitted over the study duration (16
years, n=873) at the CHUV, we found that 1% (n=9) were due
to VBD.3.2. Vertebrobasilar thrombosis and ischemia
A thrombus within the VBD was detected (radiologically and/or
pathologically; Fig. 2) in 60% of all patients, and in 79% of
patients with acute clinical change shortly before SAH. In turn,392% of patients with a VBD thrombus presented new or
worsened neurological signs. Hence, the presence of thrombosis
was associated with clinical change before SAH (x2=4.38, P=
0.04). Brainstem, pontine, or cerebellar infarction was conﬁrmed
in 45% of all patients on MRI (Fig. 2). Ischemia was present in
64% of patients with change in neurological status prior to SAH,
and in 75% of patients with VBD thrombosis. There was a
signiﬁcant association between basilar thrombosis and radiolog-
ically detectable infarction (x2=8.09, P=0.005).3.3. Cardiovascular risk factors
All but 1 patient (95%) were known to have arterial
hypertension. A total of 45% of the patients were smokers,
20% diabetic, and 50% had dyslipidemia. Leukoaraiosis was
present in 84% (data not available in 1 patient). Supplementary
radiological ﬁndings and/or previous medical history revealed
concomitant intra- or extracranial vascular and organ abnor-
malities in 65% of the patients, such as anterior cerebral
circulation aneurysms or dolichoectasia, aortic aneurysms and
dilatation, and polycystic kidney disease. None of the patients
had a speciﬁc diagnosis of an underlying collagen or other genetic
disorder, but none underwent genetic testing.3.4. Treatment and outcome
Early case fatality in this serieswas65%.Most patients diedwithin
1 day after SAH (median 24hours, IQR 66.25, range 2–264
hours). Three patients survived until 9 to 11 days post-SAH. One
patient had already had an initial SAHdue to VBD 2months prior
to the index SAH. Neither hemorrhage was preceded by clinical
symptoms, with the second event being fatal. Preceding posterior
circulation ischemia was signiﬁcantly associated with fatal
outcome (x2=6.24,P=0.01),whereas vertebrobasilar thrombosis
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chronic VBD symptoms before SAHwas not signiﬁcantly different
to that in patientswithout knownVBD(31%vs43%, respectively;
x2=0.002, P>0.05). In our patients, except for headache, every
symptom acutely appearing or worsening before SAH (Table 1B)
was associated with ponto-cerebellar ischemia and fatal outcome.
Overall, recent clinical deterioration before SAH did not inﬂuence
survival rate (35% vs 33%, respectively; x2=0.01, P>0.05). The
following analysis on therapeutic management is therefore
presented across all patients.
Prior to the index event, 45% of the patients were treated with
antiplatelet agents (7 patients on aspirin, 1 on clopidogrel, and 1
on both) for a median duration of 60 months (IQR 24, range
6–180 months). Three patients were anticoagulated with vitamin
K antagonists for a median duration of 3 years (IQR 6.84, range
0.33–14 years), with 1 taking aspirin concurrently. Ischemia in
our VBD patients was present irrespective of preventive
antithrombotic therapy (x2=0.25, P>0.05). In regard to acute
management strategies, following clinical deterioration, aspirin
was introduced in 6 patients at a median of 5 days (IQR 4, range
2–7 days), and therapeutic heparin in 3 patients (all had been on
long-term aspirin) at a median of 2 days (IQR 1.75, range 0.5–4
days) before SAH. Given the short interval between admission
and SAH, patients on chronic aspirin that were anticoagulated
after clinical deterioration were considered being on double
antithrombotic treatment at time of SAH.
All 5 patients on double antithrombotic treatment died. Of the
10 patients on antiplatelet drugs alone, 50% survived the SAH.
One patient was on a vitamin K antagonist alone at time of SAH
and survived. Four patients did not receive any antithrombotic
treatment and 3 of them passed away (only 1 of them with prior
clinical deterioration, the other 3 with sudden-onset SAH). The
patient who survived underwent complex endovascular treat-
ment.3.5. Pathological examination
Autopsy in 6 patients from the CHUV conﬁrmed SAH resulting
from ruptured VBD (Fig. 1B). All autopsied patients had acute
brainstem ischemia and thrombosis within the VBD. In 1 patient,
thrombosis was diagnosed through pathological examination
only. We found multilayer thrombi indicating turbulent blood
ﬂow with stasis close to the arterial wall as the principal
mechanism for thrombus formation. Most of the patients had
signs of acute-on-chronic thrombosis. Despite substantial
enlargement of the artery, only a small residual lumen was
detectable in these patients (Fig. 2B).
In terms of VBD pathogenesis, degeneration of the internal
elastic lamina, intramural hematoma, defects of the media smooth
muscle layer and arterial wall ﬁbrosiswere observed. Therewas no
signiﬁcant burdenof atherosclerotic changes.Although, in general,
rupture site was at the same level as the thrombus (Fig. 2B), due to
extensive chronicwall abnormalities and limited transformation of
collagenous tissue following ischemia, pathological examination
did not allow clarifying whether vessel rupture was primarily due
to ischemia of the arterial wall through thrombus compression or
occlusion of vasa vasorum.4. Discussion
Our multicenter retrospective study indicates that SAH in VBD is
often heralded by new or worsened symptoms from ponto-
cerebellar ischemia associated with endoluminal thrombus4formation, conﬁrming previous accounts of potentially fatal
SAH following clinical and radiological signs of posterior
circulation ischemia in patients with VBD.[15,17–21,23–25] VBD
appears to represent a rare cause of SAH (∼1% of patients
admitted with SAH in the CHUV cohort); however, it is quite a
precarious one, given a case fatality of 65%which corresponds to
nearly twice the SAH fatality in general.[26]
Ischemia in VBD is thought to be caused by a combination of
reduced blood ﬂow, thrombus formation, thromboembolism,
perforator occlusion, and shear stress.[3,6,15,27] Most of our
pathologically examined patients hadmultilayer acute-on-chronic
thrombi indicating progressive thrombosis due to perturbed blood
ﬂow. The mechanisms leading to rupture of VBD and SAH may
involve decreasing arterial wall resistance from progressive
dilatation (Laplace’s law), absence of protective intimal thickening
within the VBD, inﬂammation and ischemia of the vessel wall
through local effects by the thrombus or occlusion of vasa
vasorum.[28] Artery wall thinning due to spontaneous or induced
lysis may have also contributed to rupture and SAH, as previously
suggested.[19] Vertebrobasilar thrombosis and ponto-cerebellar
ischemia were tightly linked to acute clinical change. In those 3
patients with acute clinical symptoms but without vertebrobasilar
thrombosis, we assume that symptoms preceding SAH resulted
from compression of adjacent structures by VBD enlargement.
This agrees well with previous data on increased risk of SAH in
patients with progressive VBD enlargement.[22]
The present study reveals that ponto-cerebellar ischemia
closely preceding SAH in VBD is a strong predictor of case
fatality. This poor outcome in the vast majority of our patients
indicates that combination of acute ischemia and hemorrhage in
VBD is particularly perilous. Strategic localization of this disease
in the brainstem with its vital structures may also contribute to
the high case fatality rate. Management of patients with VBD
remains controversial due to the lack of randomized controlled
trials. For ischemia in VBD, primary prevention by aspirin and
acute treatment or secondary prevention by anticoagulation
represent the only conventional treatment options.[2] Some
authors found an increased risk of hemorrhagic complications[13]
or ineffectiveness in preventing ischemia in VBD,[29] whereas
others suggest a possible survival beneﬁt.[30] A recent review is
unfavorable of secondary prevention by anticoagulation due to
the high risk of hemorrhage.[2] As to acute phase management,
while limited by inclusion criterion and small sample size, the
present observations indicate that initiation of anticoagulation or
double antithrombotic treatment may not be useful. Long
standing antiplatelet therapy may have some beneﬁcial effect.
Among other effects, this may agree with recent radiological and
histopathological data suggesting attenuation of aneurysm wall
inﬂammation through low-dose aspirin.[31] Additional prospec-
tive research is required to clarify strategies for conventional and
interventional treatments.
The observed interval of about 3 days between symptom onset
and SAH in patients with clinical change may provide an
opportunity for careful evaluation and planning of endovascular
treatment or surgery. Endovascular reconstruction and emboliza-
tion is achieved through combining stents, coils, and ﬂow
diverters.[32,33] Surgical interventions include parent vessel occlu-
sion,[34]decompressionandrepositioning,[11]andveinbypasses.[35]
Interventions in VBD remain experimental and associated with
considerable rates of severe complications: 10% to 30 % for
endovascular and 12% to 15 % for surgical procedures.[32–34] A
long-term follow-up study on stent-assisted endovascular repair
showed satisfactory results in 8 out of 9 patients with VBD,
[14] Passero S, Filosomi G. Posterior circulation infarcts in patients with
Sokolov et al. Medicine (2016) 95:27 www.md-journal.comincluding 2 suffering from acute SAH, with 1 of the 9 patients
passing away 2 weeks after intervention.[36] In our study, the only
patient undergoing complex endovascular treatment following
spontaneous SAH survived, with excellent evolution.
Limitations of our study include the partially nonconsecutive
collection of patients within multiple centers, moderate sample
size and heterogeneous treatment approaches, somewhat limiting
statistical inferences.5. Conclusion
In summary, this clinico-pathological study conﬁrms a patho-
physiological association between SAH and preceding acute
clinical deterioration due to vertebrobasilar thrombosis in
patients with VBD. As compared to other SAH etiologies, case
fatality due to SAH in VBD is twice as high, and higher in those
with concurrent posterior circulation ischemia. Despite limita-
tions, the data suggest initiation of anticoagulation after clinical
worsening in VBD may not be useful. In addition, the ﬁndings
reveal a short therapeutic window of 3 days during which
endovascular or surgical intervention might be evaluated on an
individual basis, until randomized interventional data become
available.Acknowledgments
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